Masuoka K. Lorianne - Mar 2, 2023 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC. (OPNT)

Role
Director
Signature
/s/ Lorianne Masuoka
Stock symbol
OPNT
Transactions as of
Mar 2, 2023
Transactions value $
-$80,000
Form type
4
Date filed
3/3/2023, 08:05 AM
Previous filing
Jun 14, 2022
Next filing
Jan 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPNT Common Stock Disposed to Issuer -$40K -2K -50% $20.00 2K Mar 2, 2023 Direct F1
transaction OPNT Common Stock Disposed to Issuer -$40K -2K -100% $20.00 0 Mar 2, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPNT Stock Option (right to buy) Award $0 -5K -100% $0.00* 0 Mar 2, 2023 Common Stock 5K $10.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Masuoka K. Lorianne is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2 Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3 The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.